Literature DB >> 9716075

Lyme borreliosis.

R B Nadelman1, G P Wormser.   

Abstract

Lyme borreliosis (Lyme disease) is often said to be associated with "protean" manifestations, a reference to the ancient god Proteus, who could assume many forms and thus elude his pursuers. This legendary quality has clouded our understanding of Lyme borreliosis by giving Borrelia burgdorferi infection a mythical aura of its own. This review shows that this illness, while incompletely understood, is far more palpable than Proteus and is (in most cases) much more readily subdued. The clinical presentations of Lyme borreliosis do differ in North America and Eurasia, possibly due to the differing pathogenicity of distinct genospecies of Borrelia burgdorferi. The most common manifestation, however, in both continents is erythema migrans. Diagnosis should rest on a careful history and objective clinical findings, supported by appropriately chosen laboratory tests. Reports of coinfection with other tick-borne diseases should prompt a fresh look at Lyme borreliosis. Assertions about "protean manifestations" of B burgdorferi infection should be reappraised. Advances in laboratory techniques are welcome but culture remains the gold standard for the diagnosis--and no laboratory test result should substitute for careful clinical observation and critical analysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716075     DOI: 10.1016/S0140-6736(98)01146-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  87 in total

1.  Lyme borreliosis in Ontario: determining the risks.

Authors:  I K Barker; L R Lindsay
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

2.  Characterization of Borrelia burgdorferi isolated from erythema migrans lesions: interrelationship of three molecular typing methods.

Authors:  R Iyer; D Liveris; A Adams; J Nowakowski; D McKenna; S Bittker; D Cooper; G P Wormser; I Schwartz
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 3.  Laboratory testing for Lyme disease: possibilities and practicalities.

Authors:  Kurt D Reed
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine.

Authors:  Adriana R Marques; Dale S Martin; Mario T Philipp
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

5.  Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice.

Authors:  C Ekerfelt; M Andersson; A Olausson; S Bergström; P Hultman
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

6.  Comparison of immunofluorescence assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme borreliosis.

Authors:  Tjasa Cerar; Eva Ruzic-Sabljic; Joze Cimperman; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

Review 7.  Borrelia burgdorferi and tick proteins supporting pathogen persistence in the vector.

Authors:  Faith Kung; Juan Anguita; Utpal Pal
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

8.  Characterization of the stringent response and rel(Bbu) expression in Borrelia burgdorferi.

Authors:  Julia Bugrysheva; Elena Y Dobrikova; Marina L Sartakova; Melissa J Caimano; Thomas J Daniels; Justin D Radolf; Henry P Godfrey; Felipe C Cabello
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

9.  BBK07, a dominant in vivo antigen of Borrelia burgdorferi, is a potential marker for serodiagnosis of Lyme disease.

Authors:  Adam S Coleman; Utpal Pal
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  The BosR regulatory protein of Borrelia burgdorferi interfaces with the RpoS regulatory pathway and modulates both the oxidative stress response and pathogenic properties of the Lyme disease spirochete.

Authors:  Jenny A Hyde; Dana K Shaw; Roger Smith Iii; Jerome P Trzeciakowski; Jon T Skare
Journal:  Mol Microbiol       Date:  2009-11-10       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.